FDA Quick Tracks HDP-101 For A number of Myeloma

HDP-101 was proven to have produced vital preliminary efficacy with a manageable toxicity profile in information from the section 1 HDP-101-01 trial shared on the twenty first Annual Worldwide Myeloma Society Assembly and Exposition in 2024, in response to a report from CURE’s sister publication, CancerNetwork.

In cohort 5 of the trial, through which sufferers obtained HDP-101 at 100 μg/kg, 5 of six sufferers noticed a lower in paraprotein % adjustments from screening. Furthermore, three had a partial response (PR) or higher, and one skilled a whole response (CR), in response to the report.

Widespread any-grade and grade 3 (extreme) or 4 (life-threatening) treatment-emergent negative effects, respectively, included thrombocytopenia (56% versus 39%), arthralgia (33% versus 0%), anemia (33% versus 22%), fatigue (28% versus 0%) and neutropenia (22% vs 17%).

The trial, in response to its itemizing on clinicaltrials.gov, launched on Feb. 7, 2022 and has an estimated main completion date of August 2025, adopted by an approximate examine completion date of Might 2026.

In keeping with the itemizing, the trial remains to be recruiting sufferers and can finally enroll an estimated 78 sufferers with relapsed or refractory a number of myeloma. The trial is at present being performed at 16 websites in the USA, Germany, Hungary and Poland, with U.S. places together with The College of Texas MD Anderson Most cancers Heart in Houston, Winship Most cancers Institute of Emory College in Atlanta and The Tisch Most cancers Institute at Mount Sinai in New York.

An antibody-drug conjugate akin to HDP-101, as outlined by the Nationwide Most cancers Institute on its web site, is a substance made up of a monoclonal antibody chemically linked to a drug. Upon administration, the monoclonal antibody binds to particular proteins or receptors discovered on sure varieties of cells, akin to most cancers cells, and the linked drug enters these cells and kills them with out harming different cells.

HDP-101 remains to be an investigational product that has not obtained advertising approval from any regulatory authority, such because the FDA, the information launch clarifies, noting that the security and efficacy of the investigational compound are at present being evaluated and should not but established.

For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.

References:

1. “PR: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Quick Observe Designation by US FDA for the Therapy of A number of Myeloma,” information launch; https://heidelberg-pharma.com/en/press-investors/bulletins/press-releases-and-ad-hoc-announcements/pr-heidelberg-pharmas-lead-adc-candidate-hdp-101-granted-fast-track-designation-by-us-fda-for-the-treatment-of-multiple-myeloma
2. “Quick Observe,” FDA; https://www.fda.gov/sufferers/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
3. “HDP-101 Demonstrates Preliminary Efficacy in R/R A number of Myeloma,” CancerNetwork; https://www.cancernetwork.com/view/hdp-101-demonstrates-preliminary-efficacy-in-r-r-multiple-myeloma
4. “Research to Assess Security of HDP-101 in Sufferers With Relapsed Refractory A number of Myeloma;” https://www.clinicaltrials.gov/examine/NCT04879043?a=5#contacts-and-locations
5. “Antibody-drug conjugate;” https://www.most cancers.gov/publications/dictionaries/cancer-terms/def/antibody-drug-conjugate